newsfilter
← Latest News
ACCESS Newswire·

NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives

SHELTON, CT / ACCESS Newswire / October 5, 2026 / NanoViricides, Inc. , a clinical stage leader developing antiviral drugs that viruses cannot escape, herewith provides additional